-
1. Solanki S, Rathi M, Khanduja S, et al. Recent trends: Medical management of infectious keratitis. Oman J Ophthalmol 2015; 8(2): 83-85.
-
2. Hooper DC, Wolfson JS. The fluoroquinolones: pharmacology, clinical uses, and toxicities in humans. Antimicrob Agents Chemother 1985; 28(5): 716-721.
-
3. Deschênes J, Blondeau J. Besifloxacin in the management of bacterial infections of the ocular surface. Can J Ophthalmol 2015; 50(3): 184-191.
-
4. Park HS, Lee JH, Kim HK. Comparative clinical study of conjunctival toxicities of newer generation fluoroquinolones without the influence of preservatives. Int J Ophthalmol 2015; 8(6): 1220-1223.
-
5. Dowell SF, Schwartz B, Phillips WR. Appropriate use of antibiotics for URIs in children: Part II. Cough, pharyngitis and the common cold. The Pediatric URI Consensus Team. Am Fam Physician 1998; 58(6): 1335-1342, 1345.
-
6. Cohen FL, Tartasky D. Microbial resistance to drug therapy: a review. Am J Infect Control 1997; 25(1): 51-64.
-
7. Baquero F. Evolving resistance patterns of Streptococcus pneumoniae: a link with long-acting macrolide consumption? J Chemother 1999; 11 Suppl 1: 35-43.
-
8. Scoper SV. Review of third-and fourth-generation fluoroquinolones in ophthalmology: in-vitro and in-vivo efficacy. Adv Ther 2008; 25(10): 979-994.
-
9. Huz JI, Mukkamala K, Pagan IR, et al. Clinical outcomes and antibiotic susceptibilities of Staphylococcus aureus endophthalmitis. Graefes Arch Clin Exp Ophthalmol 2016 Oct 19 [Epub ahead of print].
-
10. Papa V, Blanco AR, Santocono M. Ocular flora and their antibiotic susceptibility in patients having cataract surgery in Italy. J Cataract Refract Surg 2016; 42(9): 1312-1317.